Reuters logo
BRIEF-Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO
March 6, 2017 / 11:12 AM / in 7 months

BRIEF-Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO

March 6 (Reuters) - Advaxis Inc

* Advaxis announces FDA acceptance of IND for groundbreaking personalized neoepitope immunotherapy, ADXS-NEO

* Plans to initiate a phase 1 trial evaluating ADXS-NEO in multiple tumor types later this year Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below